Rascol, O <br/><br/>
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.  [electronic resource] 

 -  Movement disorders : official journal of the Movement Disorder Society  Jul 2001 
 - 708-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0885-3185 
<br/><br/><label>Standard No.: </label>10.1002/mds.1143  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adrenergic alpha-Antagonists--adverse effects<br/>Aged<br/>Antiparkinson Agents--adverse effects<br/>Dose-Response Relationship, Drug<br/>Dyskinesia, Drug-Induced--drug therapy<br/>Female<br/>Humans<br/>Idazoxan--adverse effects<br/>Levodopa--adverse effects<br/>Male<br/>Middle Aged<br/>Neurologic Examination--drug effects<br/>Parkinson Disease--drug therapy<br/>Pilot Projects